Overview

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation